Top

Published in:

01-01-2014 | Editorial

What is the future of magnetic nanoparticles in the axillary management of breast cancer?

Authors: M. Ahmed, M. Douek

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Abstract

Magnetic nanoparticles (MNPs) possess unique properties, which make them highly attractive for medical applications. The use of MNPs in surgery has mainly been focused on their role in the identification of metastatic lymph node involvement. There have been developments within this field, including ongoing and newly conducted clinical trials. The current published evidence for the use of MNPs in assessing metastatic lymph node spread using sentinel lymph node biopsy and non-invasive imaging modalities is reviewed and future applications considered.

Alexiou C, Jurgons R, Seliger C, Iro H (2006) Medical applications of magnetic nanoparticles. J Nanosci Nanotechnol 6(9–10):2762–2768PubMedCrossRef

Colombo M, Carregal-Romero S, Casula MF, Gutierrez L, Morales MP, Bohm IB, Heverhagen JT, Prosperi D, Parak WJ (2012) Biological applications of magnetic nanoparticles. Chem Soc Rev 41(11):4306–4334PubMedCrossRef

Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M (2009) Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 16(10):2705–2710PubMedCrossRef

Giuliano AE, Kirgan DM, Guenther JM, Morton DL (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220(3):391–398 discussion 398–401PubMedCrossRef

Krag DN, Weaver DL, Alex JC, Fairbank JT (1993) Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 2(6):335–339 discussion 340PubMedCrossRef

Gill G (2009) Surgeons STGotRACo, Centre NCT: sentinel-lymph-node-based management or routine axillary clearance? 1-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 16(2):266–275PubMedCrossRef

Kim T, Giuliano AE, Lyman GH (2006) Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 106(1):4–16PubMedCrossRef

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10):881–888PubMedCrossRef

Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98(9):599–609PubMedCrossRef

10.

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349(6):546–553PubMedCrossRef

11.

Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, Renier M, Racano C, Carraro P, Nitti D et al (2008) A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 247(2):207–213PubMedCrossRef

12.

Mayes E, Douek M, Pankhurst Q (2012) Surgical magnetic systems and tracers for cancer staging. In: Magnetic nanoparticles: from fabrication to clinical applications. CRC Press, New York

13.

Rescigno J, Zampell JC, Axelrod D (2009) Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol 16(3):687–696PubMedCrossRef

14.

Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, Sandelin K, Derossis A, Cody H, Foulkes WD (2010) Is breast cancer the same disease in Asian and Western countries? World J Surg 34(10):2308–2324PubMedCentralPubMedCrossRef

15.

Harnan SE, Cooper KL, Meng Y, Ward SE, Fitzgerald P, Papaioannou D, Ingram C, Lorenz E, Wilkinson ID, Wyld L (2011) Magnetic resonance for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 37(11):928–936PubMedCrossRef

16.

Wang AZ, Gu F, Farokhzad OC (2009) Nanoparticles for cancer diagnosis and therapy. Safety of nanoparticles: from manufacturing to medical applications. Springer, New York

17.

Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13(6):1266–1276PubMed

18.

Swartz M (2001) The physiology of the lymphatic system. Adv Drug Deliv Rev 50:3–20PubMedCrossRef

19.

Anninga B, Ahmed M, Van Hemelrijck M, Pouw J, Westbroek D, Pinder S, Ten Haken B, Pankhurst Q, Douek M (2013) Magnetic sentinel lymph node biopsy and localization properties of a magnetic tracer in an in vivo porcine model. Breast Cancer Res Treat 141(1):33–42PubMedCrossRef

20.

Shiozawa M, Lefor AT, Hozumi Y, Kurihara K, Sata N, Yasuda Y, Kusakabe M (2013) Sentinel lymph node biopsy in patients with breast cancer using superparamagnetic iron oxide and a magnetometer. Breast Cancer 20(3):223–229PubMedCrossRef

21.

Douek M et al (2010) SentiMag Multicentre Trial (NIHR) UKCRN ID12178

22.

Joshi TP, Pankhurst QA, Hattersley S, Brazdeikis A, Hall-Craggs M, De Vita E, Bainbridge A, Sainsbury R, Sharma A, Douek M (2007) Magnetic nanoparticles for detecting sentinel lymph nodes. Eur J Surg Oncol 33(9):1135CrossRef

23.

Jain TK, Foy SP, Erokwu B, Dimitrijevic S, Flask CA, Labhasetwar V (2009) Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. Biomaterials 30(35):6748–6756PubMedCentralPubMedCrossRef

24.

Douek M, Klaase J, Monypenny I, Kothari A, Zechmeister K, Brown D, Wyld L, Drew P, Garmo H, Agbaje O, Pankhurst Q, Anninga B, Grootendorst M, ten Haken B, Hall-Craggs MA, Purushotham A, Pinder S on behalf of the SentiMAG Trialists Group (2013) Sentinel node biopsy using a magnetic tracer versus standard technique: The SentiMAG Multicentre Trial. Ann Surg Oncol. doi:10.1245/s10434-013-3379-6

25.

Harada T, Tanigawa N, Matsuki M, Nohara T, Narabayashi I (2007) Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur J Radiol 63(3):401–407PubMedCrossRef

26.

Motomura K, Ishitobi M, Komoike Y, Koyama H, Noguchi A, Sumino H, Kumatani Y, Inaji H, Horinouchi T, Nakanishi K (2011) SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer. Ann Surg Oncol 18(12):3422–3429PubMedCrossRef

27.

Madru R, Kjellman P, Olsson F, Wingardh K, Ingvar C, Stahlberg F, Olsrud J, Latt J, Fredriksson S, Knutsson L et al (2012) 99mTc-labeled superparamagnetic iron oxide nanoparticles for multimodality SPECT/MRI of sentinel lymph nodes. J Nucl Med 53(3):459–463PubMedCrossRef

28.

Stadnik TW, Everaert H, Makkat S, Sacre R, Lamote J, Bourgain C (2006) Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging–initial findings. Eur Radiol 16(10):2153–2160PubMedCrossRef

29.

Michel SC, Keller TM, Frohlich JM, Fink D, Caduff R, Seifert B, Marincek B, Kubik-Huch RA (2002) Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 225(2):527–536PubMedCrossRef

30.

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252(3):426–432 discussion 432-423PubMed

31.

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305PubMedCrossRef

32.

Kimura K, Tanigawa N, Matsuki M, Nohara T, Iwamoto M, Sumiyoshi K, Tanaka S, Takahashi Y, Narumi Y (2010) High-resolution MR lymphography using ultrasmall superparamagnetic iron oxide (USPIO) in the evaluation of axillary lymph nodes in patients with early stage breast cancer: preliminary results. Breast Cancer 17(4):241–246PubMedCrossRef

33.

Johnson L, Pinder SE, Douek M (2013) Deposition of superparamagnetic iron-oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection. Histopathology 62(3):481–486PubMedCrossRef

34.

Peare R, Staff RT, Heys SD (2010) The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat 123(1):281–290PubMedCrossRef

35.

Torres Martin de Rosales R, Finucane C, Mather SJ, Blower PJ (2009) Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases. Chem Commun 32:4847–4849CrossRef

36.

Torres Martin de Rosales R, Tavare R, Glaria A, Varma G, Protti A, Blower PJ (2011) ((9)(9)m)Tc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging. Bioconjug Chem 22(3):455–465PubMedCrossRef

37.

Cooper KL, Harnan S, Meng Y, Ward SE, Fitzgerald P, Papaioannou D, Wyld L, Ingram C, Wilkinson ID, Lorenz E (2011) Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 37(3):187–198PubMedCrossRef

Title: What is the future of magnetic nanoparticles in the axillary management of breast cancer?
Authors: M. Ahmed
M. Douek
Publication date: 01-01-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2801-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers

The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer

Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells

Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS)

Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience

Prospective associations of depression with survival: a population-based cohort study in patients with newly diagnosed breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer